Therapeutic Areas
Therapeutic Areas
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease (DED).1 TRYPTYR is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to rapidly increase natural tear production.1
1 TRYPTYR® U.S. FDA Prescribing Information. 2025.
Recent Scientific Publications
DRY EYE
AR-15512 Registration Clinical Studies
DRY EYE
A Review of Phase 3 Trial Results for Acoltremon (AR-15512) Ophthalmic Solution 0.003%
DRY EYE
AR-15512: Results of Phase 3 Studies for Acoltremon Ophtalmic Solution 0.003%, a Novel TRPM8 Agonist
PIPELINE FOCUS
We continue to build our pharmaceutical pipeline focusing on promising and large categories.